Stem Cell-Based Toxicity Screening
- 122 Downloads
Preclinical cell-based toxicity screening is an essential stage in the drug development process. Current technology is based on immortalized cell lines, rodent cells and primary human hepatocytes, all of which suffer from shortcomings. Cell lines and rodent cells have limited relevance to human physiology, while primary human cells remain a scarce and variable resource. These systems are inadequate, as evidenced by the high levels of compound attrition in the clinical trial and postmarketing stages of development, producing safety risks and high financial costs. Hepatotoxicity and drug-induced liver injury account for a substantial proportion of compound failures, highlighting the need for accurate and predictive liver toxicity models. Pluripotent stem cell-derived hepatocyte-like cells offer a means of creating physiologically relevant drug screening assays that could serve as an additional method of detecting toxicity in the lead optimization phase of drug development. The scalability and definition of pluripotent cell culture systems are constantly improving, bringing a potentially inexhaustible cell resource closer to industrial translation. Meanwhile, increased understanding of pluripotency, differentiation and reprogramming, combined with optimization of tissue culture environments, will allow the ongoing issues of hepatocyte lifespan and immature function to be addressed. In future, extensive validation of stem cell-derived hepatocyte-like cells against existing drug screening methods will be required if they are to be established as a standard tool for investigating drug toxicity.
KeywordsPluripotent Stem Cell iPSC Definitive Endoderm Primary Human Hepatocyte Drug Development Process
Mr Sebastian Greenhough was supported by a Knowledge Transfer Partnership award and Roslin Cellab Ltd. Mr Greenhough has no other conflicts of interest to declare. Dr David Hay was supported by a Research Councils UK fellowship. Dr David Hay is a Director, Chief Scientific Officer and Shareholder in FibromEd Limited.
- 1.Gómez-Lechón MJ, Lahoz A, Gombau L, et al. In vitro evaluation of potential hepatotoxicity induced by drugs. Curr Pharm Des 2010; 16 (17): 1963–77 2. Orloff J, Douglas F, Pinheiro J, et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2010; 8 (12): 949–57PubMedCrossRefGoogle Scholar
- 2.Orloff J, Douglas F, Pinheiro J, et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2010; 8 (12): 949–57Google Scholar
- 6.Hewitt NJ, Lechon MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 2007; 39 (1): 159–234PubMedCrossRefGoogle Scholar
- 13.Medine CN, Lucendo-Villarin B, Zhou W, et al. Robust generation of metabolically active hepatocytes from pluripotent stem cells. J Vis Exp 2011 (56), e2969 [online]. Available from URL: http://www.jove.com/video/2969/robustgeneration-of-hepatocyte-like-cells-from-human-embryonic-stem-cell-populations [Accessed 2012 Jan 12]PubMedGoogle Scholar
- 26.EUR-Lex. Judgment of the court (grand chamber) of 18 October 2011. Oliver Brüstle v Greenpeace eV [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:62010J0034:EN:NOT [Accessed 2012 Jan 12]
- 41.Sekiya S, Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature 2011 29; 475 (7356): 390–3Google Scholar